经典型霍奇金淋巴瘤微环境富含CTLA-4阳性PD-1阴性T细胞
本研究利用多重免疫荧光显微镜和数字图像分析,发现经典型霍奇金淋巴瘤(cHL)微环境中富含非调节性细胞毒性T淋巴细胞相关蛋白4(CTLA-4)阳性T细胞,其数量超过PD-1阳性和LAG-3阳性T细胞。CTLA-4阳性细胞在PD-1阻断后复发的cHL肿瘤中仍存在并接触HRS细胞,提示CTLA-4:CD86相互作用参与免疫豁免微环境,PD-1阻断难治患者可能受益于CTLA-4阻断。
要点
- cHL微环境中CTLA-4阳性T细胞多于PD-1阳性和LAG-3阳性T细胞。
- HRS细胞75μm范围内CTLA-4阳性T细胞和CD86阳性TAM比例显著升高。
- PD-1阻断后复发肿瘤中仍存在CTLA-4阳性细胞接触HRS细胞,提示CTLA-4阻断潜力。
核心结论
- cHL微环境富含非Treg的CTLA-4阳性T细胞,且CTLA-4:CD86相互作用是HRS细胞周围免疫豁免生态位的组成部分。
- PD-1阻断难治的cHL患者可能从CTLA-4阻断中获益。
研究设计与样本
- 采用多重免疫荧光显微镜和数字图像分析技术,比较cHL组织与反应性淋巴组织。
- 评估T细胞表型、HRS细胞生态位(75μm范围)及PD-1阻断后复发肿瘤样本。
主要发现
- cHL中非Treg的CTLA-4阳性T细胞数量超过PD-1阳性和LAG-3阳性T细胞。
- 接触HRS细胞的T细胞中CTLA-4阳性比例高于PD-1或LAG-3阳性。
- HRS细胞和部分TAM表达CTLA-4配体CD86。
关键数值与推荐
- HRS细胞生态位定义为距离HRS细胞75μm范围内。
临床怎么用
- cHL微环境中CTLA-4高表达提示CTLA-4阻断可作为PD-1阻断难治患者的潜在治疗选择。
- 评估肿瘤微环境中CTLA-4和CD86的表达可能有助于识别适合CTLA-4阻断的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classic Hodgkin lymphoma (cHL) is a tumor composed of rare, atypical, germinal center-derived B cells (Hodgkin Reed-Sternberg [HRS] cells) embedded within a robust but ineffective inflammatory milieu. The cHL tumor microenvironment (TME) is compartmentalized into "niches" rich in programmed cell death-1 ligand (PD-L1)-positive HRS cells and tumor-associated macrophages (TAMs), which associate with PD-1-positive T cells to suppress antitumor immunity via PD-L1/PD-1 signaling. Despite the exquisite sensitivity of cHL to PD-1 checkpoint blockade, most patients eventually relapse and need therapeutic alternatives. Using multiplex immunofluorescence microscopy with digital image analysis, we found that cHL is highly enriched for non-T-regulatory, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-positive T cells (compared with reactive lymphoid tissues) that outnumber PD-1-positive and lymphocyte-activating gene-3 (LAG-3)-positive T cells. In addition, T cells touching HRS cells are more frequently positive for CTLA-4 than for PD-1 or LAG-3. We further found that HRS cells, and a subset of TAMs, are positive for the CTLA-4 ligand CD86 and that the fractions of T cells and TAMs that are CTLA-4-positive and CD86-positive, respectively, are greater within a 75 μm HRS cell niche relative to areas outside this region (CTLA-4, 38% vs 18% [P = .0001]; CD86, 38% vs 24% [P = .0007]). Importantly, CTLA-4-positive cells are present, and focally contact HRS cells, in recurrent cHL tumors following a variety of therapies, including PD-1 blockade. These results implicate CTLA-4:CD86 interactions as a component of the immunologically privileged niche surrounding HRS cells and raise the possibility that patients with cHL refractory to PD-1 blockade may benefit from CTLA-4 blockade.
引用
- Patel SS, Weirather JL, Lipschitz M, et al. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood. 2019. PMID: 31697809. doi:10.1182/blood.2019002206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。